Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
The reviews aims to summarise and quantify the overall effects of chemoprevention
Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy. For this reason, women are encouraged to try and prevent malaria infection during pregnancy by sleeping under mosquito bed-nets, and by taking drugs effective against malaria throughout pregnancy as chemoprevention.
This Cochrane Review looked at all drug regimens compared to placebo. The review authors sought to summarise and quantify the overall effects of chemoprevention. 17 trials were included, all conducted between 1957 and 2008, and all but 2 in countries of Africa.
For women in their first or second pregnancy, malaria chemoprevention prevents moderate to severe anaemia (high quality evidence); and prevents malaria parasites being detected in the blood (high quality evidence). It may also prevent malaria illness. We don’t know if it prevents maternal deaths, as this would require very large studies to detect an effect.
In their infants, malaria chemoprevention improves the average birthweight (moderate quality evidence), and reduces the number of low birthweight infants (moderate quality evidence). We are not sure if chemoprevention reduces mortality of babies in the first week, month and year, as again studies would need to be very large to show these effects.
This research is supported by the Department for International Development’s Evidence Building and Synthesis Research Programme which is led by Liverpool School of Tropical Medicine
Radeva-Petrova, D.; Kayentao, K.; ter Kuile, F.O.; Sinclair, D.; Garner, P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database of Systematic Reviews (2014) Issue 10, Art. No.: CD000169. [DOI: 10.1002/14651858.CD000169.pub3]